{
    "Trade/Device Name(s)": [
        "ImmuLisa Enhanced RNA POL III Antibody ELISA",
        "ImmuLisa\u2122 Enhanced RNA POL III Antibody ELISA"
    ],
    "Submitter Information": "IMMCO Diagnostics, Inc.",
    "510(k) Number": "K172078",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NYO"
    ],
    "Summary Letter Date": "July 7, 2017",
    "Summary Letter Received Date": "July 10, 2017",
    "Submission Date": "March 22, 2018",
    "Regulation Number(s)": [
        "21 CFR 866.5100"
    ],
    "Regulation Name(s)": [
        "Antinuclear antibody immunological test system"
    ],
    "Analyte Class(es)": [
        "autoimmune",
        "immunology"
    ],
    "Analyte(s)": [
        "Anti-RNA POL III IgG antibodies"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked immunoassay (ELISA)",
        "Solid phase immunoassay"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for ImmuLisa Enhanced RNA POL III Antibody ELISA for detection of anti-RNA polymerase III IgG antibodies in human serum",
    "Indications for Use Summary": "Qualitative or semi-quantitative detection of anti-RNA POL III IgG antibodies in human serum as an aid in diagnosis of systemic sclerosis (scleroderma) in conjunction with other laboratory and clinical findings",
    "fda_folder": "Immunology"
}